Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm
Sipuleucel-T is an autologous cellular immunotherapy approved in the US for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). This significant advance for mCRPC treatment provides healthcare professionals with another effective therapy to ex...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2016-04-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2015.1107698 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846166508005228544 |
|---|---|
| author | James L. Gulley Peter Mulders Peter Albers Jacques Banchereau Michel Bolla Klaus Pantel Thomas Powles |
| author_facet | James L. Gulley Peter Mulders Peter Albers Jacques Banchereau Michel Bolla Klaus Pantel Thomas Powles |
| author_sort | James L. Gulley |
| collection | DOAJ |
| description | Sipuleucel-T is an autologous cellular immunotherapy approved in the US for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). This significant advance for mCRPC treatment provides healthcare professionals with another effective therapy to extend survival. As an immunotherapy, sipuleucel-T possesses specific characteristics differentiating it from traditional therapies. At a roundtable meeting of experts, sipuleucel-T data were discussed, focusing on interpretation and clinical implications. Important differences between immunotherapies and traditional therapies were explored, e.g., mode of action, outcomes, data consistency and robustness, timing of sipuleucel-T treatment, and future perspectives in areas such as short-term markers of long-term benefit. |
| format | Article |
| id | doaj-art-c59d8d036807402ab5cbbf43e14090a5 |
| institution | Kabale University |
| issn | 2162-402X |
| language | English |
| publishDate | 2016-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-c59d8d036807402ab5cbbf43e14090a52024-11-15T15:56:37ZengTaylor & Francis GroupOncoImmunology2162-402X2016-04-015410.1080/2162402X.2015.1107698Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigmJames L. Gulley0Peter Mulders1Peter Albers2Jacques Banchereau3Michel Bolla4Klaus Pantel5Thomas Powles6Genitourinary Malignancies Branch and Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USARadboud University Nijmegen Medical Center, Nijmegen, The NetherlandsDüsseldorf University, Medical Faculty, Düsseldorf, GermanyJackson Laboratory for Genomic Medicine, Farmington, CT, USADepartment of Radiation Therapy, C.H.U. Grenoble, Grenoble, FranceDepartment of Tumor Biology, University Medical Center Hamburg Eppendorf, Hamburg, GermanyBarts Cancer Institute, Queen Mary University of London, London, UKSipuleucel-T is an autologous cellular immunotherapy approved in the US for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). This significant advance for mCRPC treatment provides healthcare professionals with another effective therapy to extend survival. As an immunotherapy, sipuleucel-T possesses specific characteristics differentiating it from traditional therapies. At a roundtable meeting of experts, sipuleucel-T data were discussed, focusing on interpretation and clinical implications. Important differences between immunotherapies and traditional therapies were explored, e.g., mode of action, outcomes, data consistency and robustness, timing of sipuleucel-T treatment, and future perspectives in areas such as short-term markers of long-term benefit.https://www.tandfonline.com/doi/10.1080/2162402X.2015.1107698Clinical trialsimmune responsesimmunotherapyprostate cancersipuleucel-T |
| spellingShingle | James L. Gulley Peter Mulders Peter Albers Jacques Banchereau Michel Bolla Klaus Pantel Thomas Powles Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm OncoImmunology Clinical trials immune responses immunotherapy prostate cancer sipuleucel-T |
| title | Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm |
| title_full | Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm |
| title_fullStr | Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm |
| title_full_unstemmed | Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm |
| title_short | Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm |
| title_sort | perspectives on sipuleucel t its role in the prostate cancer treatment paradigm |
| topic | Clinical trials immune responses immunotherapy prostate cancer sipuleucel-T |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2015.1107698 |
| work_keys_str_mv | AT jameslgulley perspectivesonsipuleuceltitsroleintheprostatecancertreatmentparadigm AT petermulders perspectivesonsipuleuceltitsroleintheprostatecancertreatmentparadigm AT peteralbers perspectivesonsipuleuceltitsroleintheprostatecancertreatmentparadigm AT jacquesbanchereau perspectivesonsipuleuceltitsroleintheprostatecancertreatmentparadigm AT michelbolla perspectivesonsipuleuceltitsroleintheprostatecancertreatmentparadigm AT klauspantel perspectivesonsipuleuceltitsroleintheprostatecancertreatmentparadigm AT thomaspowles perspectivesonsipuleuceltitsroleintheprostatecancertreatmentparadigm |